Drug Profile
Research programme: photodynamic therapy - Theralase/UHN/OCE
Alternative Names: TLC-3000 projectLatest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Theralase Technologies
- Class
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)
- 29 Mar 2012 Pharmacodynamics data from preclinical studies released by Theralase Technologies
- 09 Nov 2010 Theralase Technologies commences animal toxicology studies of four lead compounds